Weill Cornell, Regeneron’s New AI, Elsevier Adds Half a Million Records, More

Weill Cornell, Regeneron’s New AI, Elsevier Adds Half a Million Records, More

By Clinical Research Team

May 29, 2025 | Weill Cornell Medicine and Regeneron Pharmaceuticals collaborated to develop a new AI-based method accurately sorts cancer patients into groups that have similar characteristics before treatment and similar outcomes after treatment; Elsevier announced the addition of half a million records from ClinicalTrials.gov to its leading biomedical literature database, Embase; and more.

Illumina announced the launch of DRAGEN version 4.4 software (v4.4). The latest version of DRAGEN includes out-of-the-box oncology applications for clinical research and support for newly announced Illumina multiomics assays. Additionally, DRAGEN v4.4 continues DRAGEN's best-in-class accuracy with a 30% improvement in germline structural variant calling accuracy. DRAGEN v4.4 enhancements will simplify NGS analysis for customers while expanding their capabilities. Press release.

Imec announced their collaboration with Massachusetts Institute of Technology (MIT). The collaboration aims to develop nanoelectronics-based, minimally-invasive diagnostic devices capable of monitoring biomarkers and vital signs in clinical, point-of-care, or home settings. When combined with AI, these data enable the creation of an individual’s digital biological profile that can facilitate detailed clinical monitoring. This provides clinicians with powerful tools for therapy, diagnosis, and prevention of diseases, ultimately enhancing quality of life. Press release.

The Lupus Research Alliance (LRA) announced the launch of the Lupus Nexus Foundational Analyses, a major scientific initiative aimed at creating one of the most comprehensive and accessible lupus research datasets ever assembled. This effort will generate numerous molecular datasets using biospecimens collected through the Lupus Landmark Study, a key component of the Lupus Nexus. These molecular datasets, integrated with robust clinical data, including both clinician- and patient-reported outcomes, represent a first for a private nonprofit in the lupus research space. Press release.

Weill Cornell Medicine and Regeneron Pharmaceuticals collaborated to develop a new AI-based method accurately sorts cancer patients into groups that have similar characteristics before treatment and similar outcomes after treatment. The new approach has the potential to enable better patient selection in clinical trials and better treatment selection for individual patients. The results of the study, which was published in Nature Communications, showed that the new method’s ability to predict treatment outcomes from health record data was better than that of any other method published to date. Press release.

Altais and Autonomize AI announced a strategic partnership aimed at reducing the rising administrative burden on care management and clinical quality teams. Altais will introduce Autonomize AI Copilots—intelligent digital tools that assist care teams by handling routine administrative tasks—across Altais’ operations. Autonomize’s AI Copilots help automate time-consuming steps like gathering and summarizing cases, working alongside human teams to improve speed and consistency while keeping clinical decisions firmly in the hands of physicians and care teams. Press release.

In the largest clinical genomic profiling study of non-Hispanic Black men with metastatic prostate cancer to date, researchers from Moffitt Cancer Center, University of Pennsylvania, University of California Los Angeles, and the Veterans Affairs (VA) National Precision Oncology Program found key differences in tumor biology between non-Hispanic Black and non-Hispanic white veterans, but similar survival outcomes when both groups had equal access to care. The study, published in JAMA Network Open, analyzed data from more than 5,000 U.S. veterans with metastatic prostate cancer who underwent next-generation sequencing between 2019 and 2023. It found that while non-Hispanic Black veterans had higher rates of actionable immunotherapy targets, non-Hispanic white veterans had more frequent alterations in androgen receptor signaling and DNA repair pathways. Despite these biological differences, survival outcomes were comparable in the equal-access VA setting. Press release.

Texas Children's Hospital and The University of Texas MD Anderson Cancer Center announced a $150 million gift from Kinder Foundation. The gift creates Kinder Children's Cancer Center, a joint venture of UT MD Anderson Cancer Center and Texas Children's Hospital, with a single mission: to end childhood cancer. The gift is one of the largest philanthropic donations made to an American pediatric hospital and one of the largest in the history of the Texas Medical Center (TMC). With this support, Kinder Children's Cancer Center aims to be the nation's largest and most comprehensive cancer center focused exclusively on children. Press release.

QIAGEN has signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests. The acquisition adds Franklin, Genoox’s flagship cloud-based community platform, to the QIAGEN Digital Insights (QDI) portfolio. Press release.

datma announced the launch of advanced patient journey mapping capabilities within its flagship platform, datma.FED. Designed to provide pharmaceutical companies with a clearer view of how therapies are adopted in real-world care, this new functionality enables structured, privacy-preserving analysis of patient timelines across clinical, genomic, and diagnostic data. Press release.

Elsevier announced the addition of half a million records from ClinicalTrials.gov to its leading biomedical literature database, Embase. The integration will enable researchers to seamlessly view high-quality information on clinical research studies and their results alongside the peer-reviewed literature, in-press publications and conference abstracts already available in Embase. Researchers will be able to conduct more comprehensive evidence and literature searches while having the confidence they will never miss important updates relevant to their drug, therapy, or medical device. Press release.

Datavant announced an expanded collaboration with Boehringer Ingelheim to support the pharmaceutical company’s growing real-world evidence (RWE) initiatives. Through this partnership, Boehringer Ingelheim will leverage Datavant’s privacy-preserving tokenization and data connectivity technologies to enhance clinical development and launch strategies across 75 additional clinical trials and multiple new molecular entities. Press release.